In response to our manuscript on the eligibility for shorter treatment of multidrug-resistant tuberculosis (MDR-TB) in the European Union (EU) [1], Heldal and co-workers highlight the limitations of the surveillance data that were used to estimate the proportion of MDR-TB cases eligible for the shorter regimen, and they question the criteria that we used to define eligibility. Strict application of criteria shows that 11% of MDR-TB cases are eligible for the shorter MDR-TB regimen in the EU
No takes yet. Share an insight, caveat, or question.
Werf et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: